Loading...
Killip classification predicts mortality in patients with ST-segment-elevation MI. To assess whether Killip classification predicts 30-day and 6-month mortality in patients with non-ST-segment-elevation acute coronary syndromes (ACS), researchers pooled data from 26,090 such patients in the GUSTO IIb, PURSUIT, PARAGON A, and PARAGON B trials.
Patients in Killip classes II, III, and IV collectively made up only 11% of the study population, yet they accounted for 30% of the deaths at both 30 days and 6 months. Compared with all-cause mortality rates among patients in class I (3% at 30 days and 5% at 6 months), rates were significantly higher among patients in class II (9% and 15%, respectively) and patients in classes III-IV (14% and 23%, resp…